vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Thursday

vTv Therapeutics (NASDAQ:VTVT) is expected to issue its quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.04).

vTv Therapeutics Trading Up 1.9%

VTVT stock opened at $14.75 on Thursday. The business’s 50-day moving average price is $15.77 and its two-hundred day moving average price is $17.46. The firm has a market cap of $47.13 million, a PE ratio of -4.90 and a beta of 0.57. vTv Therapeutics has a 1-year low of $12.58 and a 1-year high of $26.99.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. HC Wainwright assumed coverage on vTv Therapeutics in a report on Wednesday, April 9th. They issued a “buy” rating and a $36.00 price target on the stock. Wall Street Zen assumed coverage on vTv Therapeutics in a report on Wednesday, April 16th. They issued a “sell” rating on the stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.